Favorable outcome for infant acute lymphoblastic leukemia after hematopoietic stem cell transplantation

David A. Jacobsohn*, Brad Hewlett, Elaine R Morgan, William T Tse, Reggie E Duerst, Morris Kletzel

*Corresponding author for this work

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Infants with acute lymphoblastic leukemia (ALL) have a poor prognosis when treated with standard chemotherapy. A subset of these infants, particularly those with mixed-lineage leukemia (MLL) rearrangements, has a high likelihood of relapse. Hematopoietic stem cell transplantation (HSCT) performed early in first remission may improve outcome. We present the results of 16 patients with infant ALL who were treated with HSCT in first remission. Six patients were ≤6 months of age at diagnosis, 11 had an initial white blood cell count of >50000/μL, and all patients with determinable cytogenetics had a high-risk karyotype [t(4:11) abnormality or other MLL rearrangement]. All patients received 150 cGy of total body irradiation for 8 doses (1200 cGy). Fifteen of 16 patients received etoposide at 1000 mg/m2 as a continuous infusion over 24 hours and cyclophosphamide at 60 mg/kg/d for 3 days. Eight patients received HSCT from an HLA-identical sibling, and 8, from unrelated cord blood. Twelve (75%) patients remain long-term survivors (median follow-up, 4.7 years). Two patients, 1 of whom had minimal residual disease at HSCT, died after relapse following HSCT. Two patients died of transplant-related causes. The HSCT was well tolerated; 15 patients achieved neutrophil engraftment at a median of 16 days. Acute and chronic graft-versus-host disease were minimal in these patients. These results support the use of HSCT in the treatment of infant ALL, especially when used as consolidation in first remission. The risk of relapse seems to be decreased with this approach. Further work is being performed to determine the long-term effects from this therapy.

Original languageEnglish (US)
Pages (from-to)999-1005
Number of pages7
JournalBiology of Blood and Marrow Transplantation
Volume11
Issue number12
DOIs
StatePublished - Dec 1 2005

Fingerprint

Hematopoietic Stem Cell Transplantation
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Recurrence
Leukemia
Whole-Body Irradiation
Residual Neoplasm
Graft vs Host Disease
Etoposide
Fetal Blood
Karyotype
Leukocyte Count
Cytogenetics
Cyclophosphamide
Survivors
Siblings
Neutrophils
Transplants
Drug Therapy

Keywords

  • Infant ALL
  • Leukemia
  • Pediatric
  • Stem cell transplant

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

@article{4d460e0a6c7044b48a78fe0a4ff88296,
title = "Favorable outcome for infant acute lymphoblastic leukemia after hematopoietic stem cell transplantation",
abstract = "Infants with acute lymphoblastic leukemia (ALL) have a poor prognosis when treated with standard chemotherapy. A subset of these infants, particularly those with mixed-lineage leukemia (MLL) rearrangements, has a high likelihood of relapse. Hematopoietic stem cell transplantation (HSCT) performed early in first remission may improve outcome. We present the results of 16 patients with infant ALL who were treated with HSCT in first remission. Six patients were ≤6 months of age at diagnosis, 11 had an initial white blood cell count of >50000/μL, and all patients with determinable cytogenetics had a high-risk karyotype [t(4:11) abnormality or other MLL rearrangement]. All patients received 150 cGy of total body irradiation for 8 doses (1200 cGy). Fifteen of 16 patients received etoposide at 1000 mg/m2 as a continuous infusion over 24 hours and cyclophosphamide at 60 mg/kg/d for 3 days. Eight patients received HSCT from an HLA-identical sibling, and 8, from unrelated cord blood. Twelve (75{\%}) patients remain long-term survivors (median follow-up, 4.7 years). Two patients, 1 of whom had minimal residual disease at HSCT, died after relapse following HSCT. Two patients died of transplant-related causes. The HSCT was well tolerated; 15 patients achieved neutrophil engraftment at a median of 16 days. Acute and chronic graft-versus-host disease were minimal in these patients. These results support the use of HSCT in the treatment of infant ALL, especially when used as consolidation in first remission. The risk of relapse seems to be decreased with this approach. Further work is being performed to determine the long-term effects from this therapy.",
keywords = "Infant ALL, Leukemia, Pediatric, Stem cell transplant",
author = "Jacobsohn, {David A.} and Brad Hewlett and Morgan, {Elaine R} and Tse, {William T} and Duerst, {Reggie E} and Morris Kletzel",
year = "2005",
month = "12",
day = "1",
doi = "10.1016/j.bbmt.2005.08.031",
language = "English (US)",
volume = "11",
pages = "999--1005",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "12",

}

Favorable outcome for infant acute lymphoblastic leukemia after hematopoietic stem cell transplantation. / Jacobsohn, David A.; Hewlett, Brad; Morgan, Elaine R; Tse, William T; Duerst, Reggie E; Kletzel, Morris.

In: Biology of Blood and Marrow Transplantation, Vol. 11, No. 12, 01.12.2005, p. 999-1005.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Favorable outcome for infant acute lymphoblastic leukemia after hematopoietic stem cell transplantation

AU - Jacobsohn, David A.

AU - Hewlett, Brad

AU - Morgan, Elaine R

AU - Tse, William T

AU - Duerst, Reggie E

AU - Kletzel, Morris

PY - 2005/12/1

Y1 - 2005/12/1

N2 - Infants with acute lymphoblastic leukemia (ALL) have a poor prognosis when treated with standard chemotherapy. A subset of these infants, particularly those with mixed-lineage leukemia (MLL) rearrangements, has a high likelihood of relapse. Hematopoietic stem cell transplantation (HSCT) performed early in first remission may improve outcome. We present the results of 16 patients with infant ALL who were treated with HSCT in first remission. Six patients were ≤6 months of age at diagnosis, 11 had an initial white blood cell count of >50000/μL, and all patients with determinable cytogenetics had a high-risk karyotype [t(4:11) abnormality or other MLL rearrangement]. All patients received 150 cGy of total body irradiation for 8 doses (1200 cGy). Fifteen of 16 patients received etoposide at 1000 mg/m2 as a continuous infusion over 24 hours and cyclophosphamide at 60 mg/kg/d for 3 days. Eight patients received HSCT from an HLA-identical sibling, and 8, from unrelated cord blood. Twelve (75%) patients remain long-term survivors (median follow-up, 4.7 years). Two patients, 1 of whom had minimal residual disease at HSCT, died after relapse following HSCT. Two patients died of transplant-related causes. The HSCT was well tolerated; 15 patients achieved neutrophil engraftment at a median of 16 days. Acute and chronic graft-versus-host disease were minimal in these patients. These results support the use of HSCT in the treatment of infant ALL, especially when used as consolidation in first remission. The risk of relapse seems to be decreased with this approach. Further work is being performed to determine the long-term effects from this therapy.

AB - Infants with acute lymphoblastic leukemia (ALL) have a poor prognosis when treated with standard chemotherapy. A subset of these infants, particularly those with mixed-lineage leukemia (MLL) rearrangements, has a high likelihood of relapse. Hematopoietic stem cell transplantation (HSCT) performed early in first remission may improve outcome. We present the results of 16 patients with infant ALL who were treated with HSCT in first remission. Six patients were ≤6 months of age at diagnosis, 11 had an initial white blood cell count of >50000/μL, and all patients with determinable cytogenetics had a high-risk karyotype [t(4:11) abnormality or other MLL rearrangement]. All patients received 150 cGy of total body irradiation for 8 doses (1200 cGy). Fifteen of 16 patients received etoposide at 1000 mg/m2 as a continuous infusion over 24 hours and cyclophosphamide at 60 mg/kg/d for 3 days. Eight patients received HSCT from an HLA-identical sibling, and 8, from unrelated cord blood. Twelve (75%) patients remain long-term survivors (median follow-up, 4.7 years). Two patients, 1 of whom had minimal residual disease at HSCT, died after relapse following HSCT. Two patients died of transplant-related causes. The HSCT was well tolerated; 15 patients achieved neutrophil engraftment at a median of 16 days. Acute and chronic graft-versus-host disease were minimal in these patients. These results support the use of HSCT in the treatment of infant ALL, especially when used as consolidation in first remission. The risk of relapse seems to be decreased with this approach. Further work is being performed to determine the long-term effects from this therapy.

KW - Infant ALL

KW - Leukemia

KW - Pediatric

KW - Stem cell transplant

UR - http://www.scopus.com/inward/record.url?scp=28744431906&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=28744431906&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2005.08.031

DO - 10.1016/j.bbmt.2005.08.031

M3 - Article

VL - 11

SP - 999

EP - 1005

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 12

ER -